The Dana-Farber/Harvard Cancer Center (DF/HCC) is a Harvard-wide, NCI-designated Comprehensive Cancer Center. This training grant is the principal instrument of basic science training at DF/HCC. Our broad goal is to teach young scientists at the predoctoral and postdoctoral levels how to apply emerging technology in genomics and proteomics to fundamental problems in cell division, cell differentiation or cell death (""""""""the three D's"""""""" of cancer cell biology) that underlie human neoplastic disease. We propose to appoint 5 predoctoral and 12 postdoctoral scientists per year. Our pre-doctoral trainees will be selected from a pool of students who have enrolled in a newly created Cancer Biology Track in the Harvard Biological and Biomedical Sciences. These students will be appointed after their second year of study when they have completed laboratory rotations and chosen one of our mentors as their thesis advisor. The postdoctoral appointments will be for recent recipients of the Ph.D. or M.D./Ph.D. degrees. We are especially selective with our postdoctoral appointments. By multiple metrics the postdoctoral trainees appointed to our program in years past have been every bit as successful as postdoctoral fellows supported by individual awards from other funders, such as NRSA, ACS and Damon-Runyon. Funding for Clinical training is excluded from this program. Laboratory training in cancer research is complemented by a didactic program that prepares our students to exploit a broad range of job opportunities in settings ranging from the small liberal arts college, to academic medical research institutes and the biotechnology industry. Programs provided by the Postdoctoral and Graduate Student Affairs Office at Dana-Farber, which are available for all our trainees, enhance trainee cohesiveness and program identity. The didactic and one-one-one training is complemented by retreats and poster sessions that draw students, postdocs and their mentors from all major components of DF/HCC. On a tactical level, each Department/Division within DF/HCC has journal clubs and seminar programs that provide a sense of local community.

Public Health Relevance

Cancer continues to be a major cause of morbidity and mortality in the USA, and more than 40% of people will develop cancer at some point in their lives. Training scientists who will develop the next generations of cancer diagnostics and treatments is a critical priority. A distinguishing feature of this training Program is that all of the preceptors have ongoing or developing relationships with DF/HCC clinical programs in one or more of the major human cancers. These nodal points between clinicians and basic scientists help to initiate and sustain a cancer focus in our trainees. Many of our prior trainees have already made the transition to scientific independence. Their discovery-oriented basic research has contributed in substantive ways to a new generation of targeted therapies for cancer such as Gleevec, Iressa, Herceptin, and Avastin.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Jordan, Nicole Vincent; Bardia, Aditya; Wittner, Ben S et al. (2016) HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature 537:102-106
Olenchock, Benjamin A; Moslehi, Javid; Baik, Alan H et al. (2016) EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection. Cell 164:884-95
Yang, Xinping; Coulombe-Huntington, Jasmin; Kang, Shuli et al. (2016) Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing. Cell 164:805-17
Chadwick, Emily J; Yang, David P; Filbin, Mariella G et al. (2015) A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies. J Vis Exp :e53304
Eisner, Adriana; Pazyra-Murphy, Maria F; Durresi, Ershela et al. (2015) The Eya1 phosphatase promotes Shh signaling during hindbrain development and oncogenesis. Dev Cell 33:22-35
Xie, Jenny; Kim, Hyungjin; Moreau, Lisa A et al. (2015) RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway. J Clin Invest 125:1523-32
Smith, Jennifer A; Haberstroh, Friederike S; White, Elizabeth A et al. (2014) SMCX and components of the TIP60 complex contribute to E2 regulation of the HPV E6/E7 promoter. Virology 468-470:311-21
Engel, Ulrike; Zhan, Yougen; Long, Jennifer B et al. (2014) Abelson phosphorylation of CLASP2 modulates its association with microtubules and actin. Cytoskeleton (Hoboken) 71:195-209
Persson, Laura; Witt, Rochelle M; Galligan, Meghan et al. (2014) Shh-proteoglycan interactions regulate maturation of olfactory glomerular circuitry. Dev Neurobiol 74:1255-67
French, Christopher A; Rahman, Shaila; Walsh, Erica M et al. (2014) NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov 4:928-41

Showing the most recent 10 out of 104 publications